Drug reference
deucravacitinib
tyrosine kinase 2 inhibitor · immunomodulator
tyrosine kinase 2 inhibitorimmunomodulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Inhibits IL-23, IL-12, and type 1 interferon pathways.
Indications
plaque psoriasis
Side effects
Common
upper respiratory infectionselevated creatine phosphokinaseherpes simplex reactivationfolliculitis
Related guidelines
Ask House about deucravacitinib
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Harrison 22e·Updated: 2026-05-10